Genetically engineered BMSCs promote dopamine secretion and ameliorate motor dysfunction in a Parkinson's disease rat model.

ABSTRACT: Regenerative therapy based on mesenchymal stem cells (MSCs) is regarded as a promising strategy for treating Parkinson's disease (PD). Previous studies have shown that mesenchymal stem cell transplantation has the potential to treat Parkinson's disease, but its specific mechanism of action is still unclear. In the present study, we generate genetically engineered bone marrow mesenchymal stem cells (BMSCs) encoding three critical genes (TH, DDC, and GCH1) for dopamine synthesis (DA-BMSCs). The DA-BMSCs maintain their MSCs characteristics and stable ability to secrete dopamine after passage. Moreover, the DA-BMSCs survived and functioned in a rat model of PD treated with 6-OHDA 8 weeks after transplantation. Histological studies showed that DA-BMSCs could differentiate into various functiona

SUBMITTER: Wang C 

PROVIDER: S-EPMC11992172 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature